11.12.2019 MagForce AG  DE000A0HGQF5

MagForce AG: 'NanoTherm School' successfully enters its second round with Module B


 


DGAP-Media / 11.12.2019 / 09:30

MagForce AG: 'NanoTherm School' successfully enters its second round with
Module B

  • MagForce successfully hosted the second session of its practice-oriented, unique, multifaceted application training for the use of the NanoTherm therapy system in treating brain tumors
  • The NanoTherm School is part of MagForce's commitment to further optimize the therapy system and educate medical professionals in its use to provide brain tumor patients with the best care possible in addition to a broad geographical coverage to provide greater accessibility
  • Participants included the team of Prof. Dr. med. habil. Jan-Peter Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus Clinic in Zwickau, where now MagForce's NanoTherm therapy system is available

Berlin, Germany and Nevada, USA, December 11, 2019 - With "Module B - Advanced Course 1: - stereotactic Instillation" MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, conducted the second round of its 'NanoTherm School' in November. The application training series was launched in January 2019 to provide the highest quality of treatment through ongoing support for physicians and certify surgeons in the use of the innovative NanoTherm technology. Same as the first session, "Module A - The Basics", which took place at the end of January 2019, Module B, focusing on advanced techniques, was met with great excitement from participants.

The NanoTherm School is part of MagForce's roll-out strategy focusing on a broad geographic coverage to provide greater availability while also constantly working on further optimizing its therapy system and educating medical professionals in its use to provide brain tumor patients with the best care possible. The training concept of NanoTherm School was developed in close collaboration with Prof. Dr. Walter Stummer, PD Dr. Dr. Oliver Grauer, and Dr. Michael Schwake, University Hospital Münster, and PD Dr. Johannes Wölfer, Hufeland Klinikum GmbH Mühlhausen, drawing on their long-standing experience in the treatment of brain tumor patients with the NanoTherm therapy system.

Participants again included the team of Prof. Dr. med. habil. Jan-Peter Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus Clinic in Zwickau, with whom MagForce entered into a cooperation agreement in June 2019. Installation of the mobile treatment center was completed in summer. The NanoActivator is now ready for use at the clinic after receipt of final approval and and is now available for the treatment of patients with brain tumors.

Prof. Dr. med. habil. Jan-Peter Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus Clinic in Zwickau, added "Innovation is extremely important in medicine and has served our patients well. Obtaining the appropriate training in new technologies and techniques is a vital part of adopting these advances into our standard treatment regimens. Practical trainings such as MagForce's NanoTherm School are therefore very welcomed as they allow neurosurgeons to ease into the method while developing the necessary skills. Thanks to the excellent preparation and support of the MagForce team, as well as the opportunity to practice NanoTherm therapy in the most practical and extremely well-structured way, we are well prepared for the use of the therapy system at our clinic starting immediately. The use of new teaching methods for advanced technologies helps us to bring outstanding inventions to patients."

About NanoTherm School
Targeted towards medical professionals working in the fields of neuro-surgery and neuro-oncology, the NanoTherm Therapy School series aims at introducing participants to the theoretical knowledge and practical techniques required to successfully apply MagForce's NanoTherm technology for the treatment of brain tumors. In practicing their skills with human specimens, participants are able to familiarize themselves with the procedures and device usages in a stress-free environment under largely real operating conditions.

The NanoTherm School is designed in three consecutive modules allowing participants to gain knowledge and understanding of MagForce's NanoTherm technology starting from basic application techniques (nanopasting) and building to advanced techniques and new surgical application forms in the final module (Module C). The practical section of the course is complemented by lectures on directly relevant aspects of NanoTherm therapy, as well as sample preparation and surgical videos. The equipment and facilities used during the course meet the requirements of today's state-of-the-art surgical equipment.

For more information about NanoTherm School, please contact:
Dipl.-Ing. Tobias Hanitsch ([email protected])
Marcel Pilz ([email protected])

About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com.
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list


Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

 

Contact:
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: [email protected]


End of Media Release


Issuer: MagForce AG
Key word(s): Health

11.12.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: [email protected]
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange
EQS News ID: 932409

 
End of News DGAP Media

932409  11.12.2019 

fncls.ssp?fn=show_t_gif&application_id=932409&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 2,58 0,47 0,72 0,07 0,84 0,62 0,00
EBITDA1,2 -1,32 -6,55 -6,74 7,43 -5,56 19,28 0,00
EBITDA-Marge3 -51,16 -1.393,62 -936,11 10.614,29 -661,90 3.109,68 0,00
EBIT1,4 -1,88 -7,46 -7,41 6,83 -6,20 18,62 0,00
EBIT-Marge5 -72,87 -1.587,23 -1.029,17 9.757,14 -738,10 3.003,23 0,00
Jahresüberschuss1 -1,55 -7,23 -7,47 4,36 -8,73 14,75 0,00
Netto-Marge6 -60,08 -1.538,30 -1.037,50 6.228,57 -1.039,29 2.379,03 0,00
Cashflow1,7 -5,13 -6,58 -5,34 -7,11 -5,67 -5,70 0,00
Ergebnis je Aktie8 -0,06 -0,28 -0,28 0,16 -0,32 0,50 -0,18
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: AIOS

INVESTOR-INFORMATIONEN
©boersengefluester.de
MagForce
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0HGQF 3,900 Halten 114,50
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 21,29 0,00 -12,58
KBV KCV KUV EV/EBITDA
3,22 - 184,37 7,21
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
Hauptversammlung
0,00 0,00 0,00 12.08.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
29.10.2021 30.06.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,93% -3,94% -21,69% 25,40%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MagForce AG  ISIN: DE000A0HGQF5 können Sie bei DGAP abrufen

Medtech , A0HGQF , MF6 , XETR:MF6